---
title: Risk willingness in multiple system atrophy and Parkinson's disease understanding
  patient preferences
date: '2024-08-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39147806/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240816182134&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Disease-modifying therapeutics in the α-synucleinopathies multiple system
  atrophy (MSA) and Parkinson's Disease (PD) are in early phases of clinical testing.
  Involving patients' preferences including therapy-associated risk willingness in
  initial stages of therapy development has been increasingly pursued in regulatory
  approval processes. In our study with 49 MSA and 38 PD patients, therapy-associated
  risk willingness was quantified using validated standard gamble scenarios for ...
disable_comments: true
---
Disease-modifying therapeutics in the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) are in early phases of clinical testing. Involving patients' preferences including therapy-associated risk willingness in initial stages of therapy development has been increasingly pursued in regulatory approval processes. In our study with 49 MSA and 38 PD patients, therapy-associated risk willingness was quantified using validated standard gamble scenarios for ...